[go: up one dir, main page]

WO2011018800A3 - Nouvelle solution formant un gel in situ pour l'administration de médicaments par voie oculaire - Google Patents

Nouvelle solution formant un gel in situ pour l'administration de médicaments par voie oculaire Download PDF

Info

Publication number
WO2011018800A3
WO2011018800A3 PCT/IN2010/000536 IN2010000536W WO2011018800A3 WO 2011018800 A3 WO2011018800 A3 WO 2011018800A3 IN 2010000536 W IN2010000536 W IN 2010000536W WO 2011018800 A3 WO2011018800 A3 WO 2011018800A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug delivery
gel forming
situ gel
ocular drug
forming solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2010/000536
Other languages
English (en)
Other versions
WO2011018800A2 (fr
Inventor
Nandan Mohan Chandavarkar
Kour Chand Jindal
Rajkumar Malayandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FDC Ltd
Original Assignee
FDC Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FDC Ltd filed Critical FDC Ltd
Publication of WO2011018800A2 publication Critical patent/WO2011018800A2/fr
Publication of WO2011018800A3 publication Critical patent/WO2011018800A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouveau système formant un gel in situ pour l'administration de médicaments par voie oculaire, qui comprend une combinaison d'un polysaccharide naturel ayant un comportement thixotropique, d'un polymère thermoréversible et d'un véhicule avec un ou plusieurs composants optionnels choisis parmi un ou plusieurs ingrédients pharmaceutiques actifs, un tampon, un conservateur avec ou sans stabilisateur, un ou plusieurs modificateurs du pH et des modificateurs de la tonicité.
PCT/IN2010/000536 2009-08-13 2010-08-13 Nouvelle solution formant un gel in situ pour l’administration de médicaments par voie oculaire Ceased WO2011018800A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1874MU2009 2009-08-13
IN1874/MUM/2009 2009-08-13

Publications (2)

Publication Number Publication Date
WO2011018800A2 WO2011018800A2 (fr) 2011-02-17
WO2011018800A3 true WO2011018800A3 (fr) 2011-07-21

Family

ID=43428604

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2010/000536 Ceased WO2011018800A2 (fr) 2009-08-13 2010-08-13 Nouvelle solution formant un gel in situ pour l’administration de médicaments par voie oculaire

Country Status (1)

Country Link
WO (1) WO2011018800A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859525B2 (en) * 2011-07-19 2014-10-14 Bausch & Lomb Incorporated Pharmaceutical compositions comprising mushroom-based polysaccharides and uses thereof
EP2836200B1 (fr) * 2012-04-08 2020-07-15 Urogen Pharma Ltd. Préparations d'hydrogel thermoréversible pour leur utilisation dans le traitement de troubles de l'urothélium
CN103977008B (zh) * 2013-02-07 2017-03-08 沈阳兴齐眼药股份有限公司 含有多佐胺和噻吗洛尔的眼用凝胶剂及其制备方法
MX364440B (es) 2013-03-15 2019-04-26 Warner Chilcott Co Llc Forma de dosis farmacéutica de cápsula de gelatina blanda con goma guar modificada.
US9757330B2 (en) 2013-10-18 2017-09-12 Industrial Technology Research Institute Recipe for in-situ gel, and implant, drug delivery system formed thereby
CN103550819A (zh) * 2013-10-31 2014-02-05 天津市中科健新材料技术有限公司 一种吸收性制品
CA3002384C (fr) * 2015-10-25 2021-02-16 Iview Therapeutics, Inc. Formulations pharmaceutiques qui forment un gel in situ
EP3512522B1 (fr) * 2017-09-02 2025-11-12 IVIEW Therapeutics, Inc. Compositions pharmaceutiques formant in situ un gel et leurs utilisations pour des maladies des sinus
CN110200904B (zh) * 2019-05-27 2021-07-23 上海昊海生物科技股份有限公司 一种降眼压缓释滴眼组合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
WO2004112836A2 (fr) * 2003-06-13 2004-12-29 Alcon, Inc. Compositions ophtalmologiques contenant une association synergique de deux polymeres
EP1911447A1 (fr) * 2005-07-11 2008-04-16 Senju Pharmaceutical Co., Ltd. Préparation de gouttes ophtalmiques comprenant de la gomme xanthique et un terpénoïde
WO2009001899A1 (fr) * 2007-06-26 2008-12-31 Wakamoto Pharmaceutical Co., Ltd. Composition aqueuse

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3700451A (en) 1970-04-06 1972-10-24 Itek Corp Gelable and gelled compositions
US4131677A (en) 1975-05-02 1978-12-26 Merck & Co., Inc. Anti-inflammatory oxazolo [5,4-b]pyridines
US4136173A (en) 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
FR2653021A1 (fr) 1989-10-17 1991-04-19 Merck Sharp & Dohme Composition ophtalmique aqueuse liquide a transition de phase liquide-gel.
FR2678832B1 (fr) 1991-07-10 1995-03-17 Europhta Sa Laboratoire Nouvelles compositions ophtalmiques a resorption amelioree et leurs procedes de preparation.
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300295A (en) * 1990-05-01 1994-04-05 Mediventures, Inc. Ophthalmic drug delivery with thermoreversible polyoxyalkylene gels adjustable for pH
US6174524B1 (en) * 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
WO2004112836A2 (fr) * 2003-06-13 2004-12-29 Alcon, Inc. Compositions ophtalmologiques contenant une association synergique de deux polymeres
EP1911447A1 (fr) * 2005-07-11 2008-04-16 Senju Pharmaceutical Co., Ltd. Préparation de gouttes ophtalmiques comprenant de la gomme xanthique et un terpénoïde
WO2009001899A1 (fr) * 2007-06-26 2008-12-31 Wakamoto Pharmaceutical Co., Ltd. Composition aqueuse
EP2172224A1 (fr) * 2007-06-26 2010-04-07 Wakamoto Pharmaceutical Co., Ltd. Composition aqueuse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COVIELLO ET AL: "Polysaccharide hydrogels for modified release formulations", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 119, no. 1, 16 April 2007 (2007-04-16), pages 5 - 24, XP022031535, ISSN: 0168-3659, DOI: DOI:10.1016/J.JCONREL.2007.01.004 *

Also Published As

Publication number Publication date
WO2011018800A2 (fr) 2011-02-17

Similar Documents

Publication Publication Date Title
WO2011018800A3 (fr) Nouvelle solution formant un gel in situ pour l'administration de médicaments par voie oculaire
BRPI0718927A2 (pt) Método de imunização contra os quatro sorotipos da dengue.
MX2009005644A (es) Gel util para el suministro de farmacos oftalmicos.
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
WO2008045635A3 (fr) Procédé et dispositif de fixation de prothèse
WO2007103666A3 (fr) Systèmes de livraison d'endoprothèse médicale implantable
WO2009073508A3 (fr) Compositions à base de gel de polysaccharide et procédés de libération prolongée de médicaments
WO2010108108A3 (fr) Dérivés de polyamine
WO2008091835A3 (fr) Endoprothèses médicales implantables
WO2007035473A3 (fr) Dispositif d'administration pharmaceutique et procede permettant de conferer un traitement oculaire
WO2007133802A3 (fr) Formules pharmaceutiques de pimavansérine
WO2010078036A3 (fr) Hydrogels biocompatibles à base de polysaccharides
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
EP2450360A3 (fr) (S)-N-Méthylnaltrexone
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
WO2006119498A3 (fr) Compositions pharmaceutiques avec liberation synchronisee de l'agent solubilisant
WO2007056205A3 (fr) Esters de carboxyalkylcellulose pour administration d'agents pharmaceutiquement actifs peu solubles
WO2007087350A3 (fr) Méthodes de régulation de la gélification de solutions de polysaccharides et leurs utilisations
WO2007147010A3 (fr) Appareils médicaux implantables et méthodes pour les fabriquer
NZ608239A (en) Aqueous drug delivery system comprising off - flavor masking agent
WO2009025926A3 (fr) Dispositifs médicaux enduits de nanoparticules et formulations permettant de traiter une maladie vasculaire
SG194175A1 (en) Polymer conjugated prostaglandin analogues
WO2011009039A3 (fr) Produit pharmaceutique pour administration par voie orale comprenant mgbg et procédés de traitement de maladie
WO2014143754A3 (fr) Implant intraoculaire contenant de la prostamide
UA102254C2 (ru) Жидкий состав для деферипрона с приятным вкусом

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10782419

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10782419

Country of ref document: EP

Kind code of ref document: A2